iTeos Therapeutics, Inc.

NasdaqGM:ITOS Stok Raporu

Piyasa değeri: US$297.0m

iTeos Therapeutics Yönetim

Yönetim kriter kontrolleri 3/4

iTeos Therapeutics CEO'su Michel Detheux, Aug2011 tarihinde atandı, in görev süresi 13.25 yıldır. in toplam yıllık tazminatı $ 5.77M olup, şirket hissesi ve opsiyonları dahil olmak üzere 10% maaş ve 90% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.058% ine doğrudan sahiptir ve bu hisseler $ 172.87K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.4 yıl ve 4.4 yıldır.

Anahtar bilgiler

Michel Detheux

İcra Kurulu Başkanı

US$5.8m

Toplam tazminat

CEO maaş yüzdesi10.0%
CEO görev süresi13.3yrs
CEO sahipliği0.06%
Yönetim ortalama görev süresi4.4yrs
Yönetim Kurulu ortalama görev süresi4.4yrs

Son yönetim güncellemeleri

Recent updates

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Nov 15
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT

Sep 15

Is iTeos Therapeutics (NASDAQ:ITOS) In A Good Position To Deliver On Growth Plans?

Aug 11
Is iTeos Therapeutics (NASDAQ:ITOS) In A Good Position To Deliver On Growth Plans?

iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism

Jul 09

iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough

Jan 25
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Looks Inexpensive But Perhaps Not Attractive Enough

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

Jan 10

Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%

May 13
Industry Analysts Just Upgraded Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Revenue Forecasts By 16%

Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding

Mar 21
Investors Give iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares A 25% Hiding

The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically

Aug 12
The Consensus EPS Estimates For iTeos Therapeutics, Inc. (NASDAQ:ITOS) Just Fell Dramatically

iTeos Therapeutics GAAP EPS of $0.16 misses by $1.04

Aug 10

iTeos Therapeutics: Too Many Unknowns

Jul 27

News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts

May 11
News Flash: Analysts Just Made A Captivating Upgrade To Their iTeos Therapeutics, Inc. (NASDAQ:ITOS) Forecasts

Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic

Nov 25
Rainbows and Unicorns: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Analysts Just Became A Lot More Optimistic

We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth

Aug 24
We Think iTeos Therapeutics (NASDAQ:ITOS) Can Afford To Drive Business Growth

iTeos Therapeutics: My Calculations Suggest Q3 Earnings Will Exceed $10 Per Share

Aug 15

GlaxoSmithKline - iTeos deal intensifies competition in anti-TIGIT space: Piper Sandler

Jun 15

We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth

Feb 07
We Think iTeos Therapeutics (NASDAQ:ITOS) Can Easily Afford To Drive Business Growth

Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions?

Dec 16
Is iTeos Therapeutics, Inc. (NASDAQ:ITOS) Popular Amongst Institutions?

iTeos Therapeutics EPS misses by $0.11

Nov 12

CEO Tazminat Analizi

Michel Detheux'un ücretlendirmesi iTeos Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$121m

Jun 30 2024n/an/a

-US$108m

Mar 31 2024n/an/a

-US$135m

Dec 31 2023US$6mUS$579k

-US$113m

Sep 30 2023n/an/a

-US$62m

Jun 30 2023n/an/a

-US$28m

Mar 31 2023n/an/a

US$12m

Dec 31 2022US$11mUS$556k

US$97m

Sep 30 2022n/an/a

US$261m

Jun 30 2022n/an/a

US$330m

Mar 31 2022n/an/a

US$298m

Dec 31 2021US$6mUS$525k

US$215m

Sep 30 2021n/an/a

US$15m

Jun 30 2021n/an/a

-US$67m

Mar 31 2021n/an/a

-US$50m

Dec 31 2020US$17mUS$463k

-US$43m

Sep 30 2020n/an/a

-US$35m

Jun 30 2020n/an/a

-US$31m

Mar 31 2020n/an/a

-US$28m

Dec 31 2019US$2mUS$460k

-US$27m

Tazminat ve Piyasa: Michel 'nin toplam tazminatı ($USD 5.77M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.47M ).

Tazminat ve Kazançlar: Michel 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Michel Detheux (57 yo)

13.3yrs

Görev süresi

US$5,767,774

Tazminat

Dr. Michel Detheux, Ph D, is Chairman of the Board at InnoSkel. He serves as an Independent Chairman at Ona Therapeutics, S.L. since December 2021.He has served as the Chief Executive Officer and Director...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Michel Detheux
President13.3yrsUS$5.77m0.058%
$ 172.9k
Matthew Gall
Chief Financial Officer4.4yrsUS$2.72m0.067%
$ 198.6k
Matthew Call
Chief Operating Officer5.3yrsUS$2.80m0.26%
$ 763.4k
Yvonne McGrath
Chief Scientific Officer2.8yrsVeri yokVeri yok
Adi Osovsky
Executive Vice President of Legal1.8yrsVeri yokVeri yok
Philippe Brantegem
Executive Vice President of Human Resources4.8yrsVeri yokVeri yok
David Feltquate
Chief Medical Officerless than a yearVeri yokVeri yok

4.4yrs

Ortalama Görev Süresi

50.5yo

Ortalama Yaş

Deneyimli Yönetim: ITOS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.4 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Michel Detheux
President12.8yrsUS$5.77m0.058%
$ 172.9k
Ann Rhoads
Independent Director4.4yrsUS$317.52k0%
$ 0
David Hallal
Independent Chairman of the Board6.4yrsUS$416.42k0%
$ 0
Timothy Van Hauwermeiren
Independent Director6.4yrsUS$303.52k0%
$ 0
Matthew Vander Heiden
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Tony W. Ho
Independent Director3.6yrsUS$305.02k0%
$ 0
Robert Iannone
Independent Director3.6yrsUS$308.27k0%
$ 0
David Lee
Independent Directorless than a yearUS$323.44kVeri yok
Gordon Freeman
Chairman of Scientific Advisory Boardno dataVeri yokVeri yok
Benoit Van den Eynde
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Florent Ginhoux
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Roberta Zappasodi
Member of Scientific Advisory Boardno dataVeri yokVeri yok

4.4yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ITOS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.4 yıldır).